Acino International AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Acino International AG - overview
Established
1836
Location
Zurich, -, Switzerland
Primary Industry
Pharmaceuticals
About
Based in Zurich, Switzerland, and founded in 1836, Acino International AG (Acino), formerly known as Schweizerhall, operates as a pharmaceutical company that develops and manufactures novel drug delivery forms. In 1994, the firm got listed in the Swiss stock exchange (ticker symbol: ACIN), and in December 2013, Nordic Capital, Avista Capital Partners, and Ardian purchased Acino in a public-to-private deal for EUR 440. 24 million. The company acquired Copharm, in 2014, and PharmaStart in 2015.
As of November 2021, Acino International AG is being led by Steffen Saltofte, as its CEO, and employs more than 2,460 employees, and operates 5 manufacturing facilities across Switzerland, Ukraine, Estonia, and South Africa. The company develops and manufactures pharmaceuticals in novel drug delivery forms, intended for the treatment of infections, nervous system disorders, urology system disorders, and cardiovascular diseases, etc, and sells medicines under the brand name, Acino Switzerland, across the markets of Middle East, Africa, Ukraine/CIS including Russia, and Latin America. Additionally, Acino International AG provides out-licensing of its in-house developed generic products, to its client companies and other pharma businesses, and furthermore offers contract manufacturing services extending from drug development, manufacturing, to packaging and logistics. As of December 2020, Acino International AG generated more than EUR 480 million in sales.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.acino.swiss
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Acino International AG - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Acino International AG | - | ||||||||
| Add-on | Completed | IlmixGroup JSC's Prescription Pharmaceutical Products and Food Supplements Brand | - | ||||||||
| Add-on | Completed | Takeda Pharmaceutical Company Limited's Middle Eastern, African and Ukrainian Primary Care Portfolio | - | ||||||||
| Secondary Buyout | Completed | Acino International AG | - | ||||||||
| Add-on | Completed | Litha Healthcare Group (PTY) Limited | - |
Displaying 1 - 5 of 11
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.